A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets

A Randomized, Open-Label, Two-Period, Two-Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Flonoltinib Maleate Tablets in Healthy Subjects Under Fed Conditions

A Randomized, Open-Label, Two-Period, Two-Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Flonoltinib Maleate Tablets in Healthy Subjects Under Fed Conditions

Study Overview

• Status: Completed
• Conditions: Heathly Subjects
• Intervention / Treatment: Drug: flunotinib

Detailed Description

Primary Study Objective. To evaluate the effect of a high-fat diet on the pharmacokinetics of single-dose oral Flonoltinib Maleate tablets in healthy subjects.

Secondary Study Objectives To evaluate the safety of single-dose oral administration of Flonoltinib Maleate Tablets under Fast or Fed condition in healthy subjects.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610000
      • Chengdu Xinhua Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. 18 to 45 years old (including 18 and 45 years old), gender is not limited;
2. Male subjects weighing ≥50.0 kg, female subjects ≥45.0 kg, with body mass index (BMI) between 19.0 and 25.0 kg/m2 (including borderline values);
3. Fully understand the content of the trial, the test drug, the trial process, etc, and be able to communicate well with the researcher, willing to comply with the study regulations, participate in the trial voluntarily and sign an Inform consent.

Exclusion Criteria:

1. Those with a history of severe allergies (e.g, angioedema and anaphylaxis), allergies (Screening Consultation/Admission Consultation) Those with a history of severe allergy (e.g, angioedema and anaphylaxis), allergy (e.g, allergy to pollen, two or more medications/foods), or history of food or drug allergy or other metabolic disorders (e.g, asthma, hives, eczematous dermatitis, etc.) judged by the investigator to be clinically significant, or a known allergy to JAK inhibitors or an allergy to excipient components of the test medication;
2. Abnormal and clinically significant results of physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (including routine blood, blood biochemistry, urine routine, blood pregnancy (only for women of childbearing age), infectious disease screening, antinuclear antibody, coagulation function, tuberculosis antibody, chest X-ray, abdominal ultrasound) prior to enrolment;
3. QTcF > 440 ms for males and > 460 ms for females on ECG during the screening period;
4. Those who have undergone major surgical procedures within 3 months prior to screening or plan to undergo surgery during the trial period;
5. Acute illness within 2 weeks prior to screening; clinically significant infection (e.g, upper respiratory tract infection, nasopharyngitis, urinary tract infection, etc.) within 3 months prior to screening; evidence of any infection within 7 days prior to screening; history of herpes simplex infection, or recurrent (>once) herpes zoster or disseminated herpes zoster;
6. History of any clinically serious disease or any disease or condition that, in the opinion of the investigator, may affect the outcome of the trial, including but not limited to a history of circulatory, endocrine, neurological, gastrointestinal, urinary, or haematological, immunological, psychiatric, and metabolic disorders;
7. Dysphagia or any history of gastrointestinal disorders (or gastrointestinal resection, etc.) affecting drug absorption; 8 . Those with irregular bowel movements and habitual constipation or diarrhoea;

9. Those with a history of lipid metabolism defects, such as: familial hyperlipidaemia, lipoid nephropathy, or patients with acute pancreatitis accompanied by hyperlipidaemia; 10. Those with a positive combined urine multi-drug test (including morphine, methamphetamine, ketamine, methylenedioxyamphetamine, tetrahydrocannabinolic acid); 11. Those with a history of previous drug abuse or drug dependence; 12. Anyone who has been vaccinated within 8 weeks prior to screening or who plan to be vaccinated during the course of the study or within 8 weeks of administration of study drug; 13. Anyone who has donated or lost ≥400 mL of blood or received a blood transfusion within 3 months prior to screening; or anyone who has donated blood or blood components within 1 month of the planned end of the trial; 14. Those with special dietary requirements or those who are unable to comply with the uniform dietary and appropriate regulations of the study center; 15. Those who have smoked more than 3 cigarettes/day or equivalent amount of tobacco in the 3 months prior to screening; or who have consumed ≥14 units of alcohol per week (1 unit equals to 17.5mL or 14g of pure alcohol, which is approximately equal to 35mL of 50° white wine or 350mL of 5° beer); or who do not agree to abstain from smoking or drinking alcohol for the duration of the trial; or those who have a positive result from an alcohol breathalyzer test; 16. Any person who has taken any prescription drug, over-the-counter drug, any vitamin product or herbal medicine (JAK inhibitor, immunosuppressant, etc.) within 14 days prior to screening; 17. Those who have combined strong inducers of liver metabolism enzymes (e.g, omeprazole, barbiturates, carbamazepine, amiloride, pallidomycin, aminoglutethimide, phenytoin, grumet, rifampicin, sulfinpyrazone, roxithromycin, etc.) within the 4 weeks (28 days) prior to Screening, or any other history of medication use that in the judgement of the Investigator has the potential to interfere with in vivo pharmacokinetics of the test drug. Anyone who has taken any drug known to cause prolongation of the QT/QTcF interval or a drug with a risk of causing torsades de pointes (TdP) within 4 weeks (28 days) prior to Screening; or drugs with a long half-life; 18. Anyone who consumed any food or drink containing caffeine (e.g. coffee, strong tea, cola, chocolate, etc.) or food containing grapefruit juice that may have an effect on metabolising enzymes or who consumed food or drink containing alcohol within 48 h prior to the administration of the drug; 19. Those who are participating in other clinical trials and have used an investigational drug, vaccine or device within 3 months prior to the first dose; 20. Pregnant or breastfeeding women or women of childbearing age who have had unprotected sex within 14 days prior to screening; 21. The subject or his/her partner is unwilling to use non-pharmacological contraception (e.g, total abstinence, condom, IUD, ligation, etc.) for contraception during the trial period or the subject and/or his/her partner has a pregnancy plan within 3 months of the administration of the study drug; 22. The subject may not be able to complete the study for other reasons or there are other factors that, in the opinion of the investigator, make participation in the trial unsuitable.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A group; Subjects received Flonoltinib Maleate: under fast condition → washout → under fed condition	Drug: flunotinib; 100mg
Experimental: B group; Subjects received Flonoltinib Maleate: under fed condition → washout → under fast condition	Drug: flunotinib; 100mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	maximum concentration	Day1 and Day11 Within 2hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
AUC0-t	Area under the blood concentration-time curve from 0 o 'clock to the last measurable concentration at collection time t	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
AUC0-∞	The area under the blood drug concentration-time curve from 0 to infinity time	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
Tmax	time to peak	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
t1/2	Terminal phase elimination half-life	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
tlag	retardation time	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
CL/F	apparent clearance	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
Vd/F	apparent volume of distribution	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
λz	Terminal elimination rate constant	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration
%AUCex	The extrapolation percentage of AUC0--∞	Day1 and Day11 Within 2 hours before administration and 0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12hours, 24hours, 48 hours, 72 hours, 96 hours, 120hours, 144 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
health checkup	General examination	Screening period, day 17 or early withdrawal
participants with abnormal vital signs	Temperature	Screening period,Day1to day7 and day11 to day17
participants with abnormal laboratory tests results	White blood cell count	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	creatinine	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	Blood pregnancy test,Only for women of childbearing age	Screening period, Day-1 ,Day 10,Day 17 or early termination
Urinary albumin creatinine ratio	Urinary albumin creatinine ratio	D-1, D17 or early termination
ECG QT Interv	12-lead electrocardiogram	Screening period, Day-1 ,Day1, Day10, Day11, Day17 or early termination
participants with abnormal vital signs	blood pressure	Screening period,Day1to day7 and day11 to day17
participants with abnormal laboratory tests results	neutrophil count	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	hemoglobin	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	platelet coun	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	red blood cell count	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	alanine aminotransferase	Screening period, D-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	aspartate aminotransferase	Screening period, D-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	total bilirubin	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	direct bilirubin	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	γ-glutamyl transpeptidase	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	Alkaline phosphatase	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	triglycerides	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
participants with abnormal laboratory tests results	total cholesterol	Screening period, Day-1 (examination results within 7 days are acceptable), Day17, or early withdrawal
adverse event	Adverse events, serious adverse events, suspected and unexpected serious adverse reactions (SUSAR), priority adverse reactions, incidence of adverse reactions	From date of randomization until the date of completion of data collection, assessed up to 17 days or early termination
participants with abnormal urinalysis	Acidity/Alkalinity	Screening period, Day-1 , Day17, or early withdrawal
participants with abnormal urinalysis	Red Blood Cells	Screening period, Day-1 , Day17, or early withdrawal
participants with abnormal urinalysis	White Blood Cells	Screening period, Day-1 , Day17, or early withdrawal
participants with abnormal urinalysis	Protein	Screening period, Day-1 , Day17, or early withdrawal
participants with abnormal urinalysis	Glucose	Screening period, Day-1 , Day17, or early withdrawal

Collaborators and Investigators

• Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd
• Investigators: Principal Investigator: Xiaolan Yong, bachelor, Chengdu Xinhua Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 4, 2024
• Primary Completion (Actual): September 11, 2024
• Study Completion (Actual): September 11, 2024

Study Registration Dates

• First Submitted: April 2, 2025
• First Submitted That Met QC Criteria: September 17, 2025
• First Posted (Estimated): September 26, 2025

Study Record Updates

• Last Update Posted (Estimated): September 26, 2025
• Last Update Submitted That Met QC Criteria: September 17, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Pharmacokinetic study; Flonoltinib Maleate Tablet; Heathly Subjects
• Other Study ID Numbers: H-FNTN-PI-FE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No